Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

67 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Uveal Melanoma UK National Guidelines.
Nathan P, Cohen V, Coupland S, Curtis K, Damato B, Evans J, Fenwick S, Kirkpatrick L, Li O, Marshall E, McGuirk K, Ottensmeier C, Pearce N, Salvi S, Stedman B, Szlosarek P, Turnbull N; United Kingdom Uveal Melanoma Guideline Development Working Group. Nathan P, et al. Among authors: szlosarek p. Eur J Cancer. 2015 Nov;51(16):2404-12. doi: 10.1016/j.ejca.2015.07.013. Epub 2015 Aug 13. Eur J Cancer. 2015. PMID: 26278648 Free article. Review.
Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma: The ATOMIC-Meso Randomized Clinical Trial.
Szlosarek PW, Creelan BC, Sarkodie T, Nolan L, Taylor P, Olevsky O, Grosso F, Cortinovis D, Chitnis M, Roy A, Gilligan D, Kindler H, Papadatos-Pastos D, Ceresoli GL, Mansfield AS, Tsao A, O'Byrne KJ, Nowak AK, Steele J, Sheaff M, Shiu CF, Kuo CL, Johnston A, Bomalaski J, Zauderer MG, Fennell DA; ATOMIC-Meso Study Group. Szlosarek PW, et al. JAMA Oncol. 2024 Apr 1;10(4):475-483. doi: 10.1001/jamaoncol.2023.6789. JAMA Oncol. 2024. PMID: 38358753 Free PMC article. Clinical Trial.
Correction: A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesothelioma.
Phillips MM, Pavlyk I, Allen M, Ghazaly E, Cutts R, Carpentier J, Berry JS, Nattress C, Feng S, Hallden G, Chelala C, Bomalaski J, Steele J, Sheaff M, Balkwill F, Szlosarek PW. Phillips MM, et al. Among authors: szlosarek pw. Pharmacol Rep. 2023 Jun;75(3):753. doi: 10.1007/s43440-023-00487-z. Pharmacol Rep. 2023. PMID: 37195562 Free PMC article. No abstract available.
A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesothelioma.
Phillips MM, Pavlyk I, Allen M, Ghazaly E, Cutts R, Carpentier J, Berry JS, Nattress C, Feng S, Hallden G, Chelala C, Bomalaski J, Steele J, Sheaff M, Balkwill F, Szlosarek PW. Phillips MM, et al. Among authors: szlosarek pw. Pharmacol Rep. 2023 Jun;75(3):570-584. doi: 10.1007/s43440-023-00480-6. Epub 2023 Apr 3. Pharmacol Rep. 2023. PMID: 37010783 Free PMC article.
Bench-to-Bedside Studies of Arginine Deprivation in Cancer.
Field GC, Pavlyk I, Szlosarek PW. Field GC, et al. Among authors: szlosarek pw. Molecules. 2023 Feb 24;28(5):2150. doi: 10.3390/molecules28052150. Molecules. 2023. PMID: 36903394 Free PMC article. Review.
BAP1 Loss Is Associated with Higher ASS1 Expression in Epithelioid Mesothelioma: Implications for Therapeutic Stratification.
Barnett SE, Kenyani J, Tripari M, Butt Z, Grosman R, Querques F, Shaw L, Silva LC, Goate Z, Marciniak SJ, Rassl DM, Jackson R, Lian LY, Szlosarek PW, Sacco JJ, Coulson JM. Barnett SE, et al. Among authors: szlosarek pw. Mol Cancer Res. 2023 May 1;21(5):411-427. doi: 10.1158/1541-7786.MCR-22-0635. Mol Cancer Res. 2023. PMID: 36669126 Free PMC article.
67 results